

**Table 8. Scenario with patients treated with nivolumab for different time periods.**

	<b>Year 1</b>	<b>Year 2</b>
Patients with MSI-H tumours treated with nivolumab (%)	8	12
Costs without nivolumab (all patients treated with chemotherapy)	£££	£££
Costs with MSI-H positive patients treated with nivolumab	£££	£££
<b>Budget impact</b>	£££	£££
£££ confidential data removed		